KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
Aim Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical laboratory analysis 2023-03, Vol.37 (5), p.e24868-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 5 |
| container_start_page | e24868 |
| container_title | Journal of clinical laboratory analysis |
| container_volume | 37 |
| creator | Mirzapoor Abbasabadi, Zohreh Hamedi Asl, Dariush Rahmani, Babak Shahbadori, Rozhin Karami, Sara Peymani, Amir Taghizadeh, Sara Samiee Rad, Fatemeh |
| description | Aim
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC.
Method
To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer.
Results
KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p |
| doi_str_mv | 10.1002/jcla.24868 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10098058</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2800626540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4498-f89971e77dc9eea472c020926842374cb3ee8428db73574db0fa74f24b5f792e3</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhi0EoqFw4QGQJS4IJcXr9a7tE1oiCqERoAJny-udTRw5drB3i_oSPDNutlTAgYttab7_nxn_CD0tyFlBCH21M06fUSZqcQ_NCiLFggpa3UczIgRfCFKUJ-hRSjtCiJBF_RCdlLUsCRdyhn5eXDZf5vjj8Xxz2ZzPsfYd_ry6KJcN3o-DHmzwOOoB0hwbZ7014aCHbXBhY412WKcUjD1ik3bYgo34EMPGhzRYg6-0GwFbj1dRe6s9NlkcwQxZbbQ3kOmsBz-kx-hBr12CJ7f3Kfp2_vbr8v1i_endatmsF4axvF8vpOQFcN4ZCaAZp4ZQImktGC05M20JkJ-ia3lZcda1pNec9ZS1Vc8lhfIUvZ58D2O7h87k3lE7dYh2r-O1CtqqvyvebtUmXKn84VKQSmSHF7cOMXwfIQ1qb5MB57SHMCZFBSE1rStGMvr8H3QXxujzfopyKWVZiJpl6uVEmRhSitDfTVOQm7ZU3eSsjjln-Nmf89-hv4PNQDEBP6yD6_9YqQ_LdTOZ_gJLA7NP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799931864</pqid></control><display><type>article</type><title>KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Mirzapoor Abbasabadi, Zohreh ; Hamedi Asl, Dariush ; Rahmani, Babak ; Shahbadori, Rozhin ; Karami, Sara ; Peymani, Amir ; Taghizadeh, Sara ; Samiee Rad, Fatemeh</creator><creatorcontrib>Mirzapoor Abbasabadi, Zohreh ; Hamedi Asl, Dariush ; Rahmani, Babak ; Shahbadori, Rozhin ; Karami, Sara ; Peymani, Amir ; Taghizadeh, Sara ; Samiee Rad, Fatemeh</creatorcontrib><description>Aim
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC.
Method
To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer.
Results
KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations.
Conclusion
Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC. To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer. KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations. Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.</description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.24868</identifier><identifier>PMID: 36930789</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies ; Biomarkers, Tumor - genetics ; BRAF ; Cancer ; Cancer therapies ; Class I Phosphatidylinositol 3-Kinases - genetics ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - genetics ; Drugs ; Exons ; Female ; Genes ; GTP Phosphohydrolases - genetics ; Humans ; Iran ; K-Ras protein ; Kinases ; KRAS ; Lymphatic system ; Male ; Medical prognosis ; Membrane Proteins - genetics ; Metastasis ; Middle Aged ; Mutation ; Mutation rates ; NRAS ; PIK3CA ; Prognosis ; Proto-Oncogene Proteins B-raf - genetics ; Proto-Oncogene Proteins p21(ras) - genetics ; Risk factors ; Survival ; Survival analysis ; Tumors ; Young Adult</subject><ispartof>Journal of clinical laboratory analysis, 2023-03, Vol.37 (5), p.e24868-n/a</ispartof><rights>2023 The Authors. published by Wiley Periodicals LLC.</rights><rights>2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4498-f89971e77dc9eea472c020926842374cb3ee8428db73574db0fa74f24b5f792e3</citedby><cites>FETCH-LOGICAL-c4498-f89971e77dc9eea472c020926842374cb3ee8428db73574db0fa74f24b5f792e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098058/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098058/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36930789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mirzapoor Abbasabadi, Zohreh</creatorcontrib><creatorcontrib>Hamedi Asl, Dariush</creatorcontrib><creatorcontrib>Rahmani, Babak</creatorcontrib><creatorcontrib>Shahbadori, Rozhin</creatorcontrib><creatorcontrib>Karami, Sara</creatorcontrib><creatorcontrib>Peymani, Amir</creatorcontrib><creatorcontrib>Taghizadeh, Sara</creatorcontrib><creatorcontrib>Samiee Rad, Fatemeh</creatorcontrib><title>KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Aim
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC.
Method
To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer.
Results
KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations.
Conclusion
Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC. To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer. KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations. Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Biomarkers, Tumor - genetics</subject><subject>BRAF</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Class I Phosphatidylinositol 3-Kinases - genetics</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Drugs</subject><subject>Exons</subject><subject>Female</subject><subject>Genes</subject><subject>GTP Phosphohydrolases - genetics</subject><subject>Humans</subject><subject>Iran</subject><subject>K-Ras protein</subject><subject>Kinases</subject><subject>KRAS</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Membrane Proteins - genetics</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Mutation rates</subject><subject>NRAS</subject><subject>PIK3CA</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Proto-Oncogene Proteins p21(ras) - genetics</subject><subject>Risk factors</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kcFuEzEQhi0EoqFw4QGQJS4IJcXr9a7tE1oiCqERoAJny-udTRw5drB3i_oSPDNutlTAgYttab7_nxn_CD0tyFlBCH21M06fUSZqcQ_NCiLFggpa3UczIgRfCFKUJ-hRSjtCiJBF_RCdlLUsCRdyhn5eXDZf5vjj8Xxz2ZzPsfYd_ry6KJcN3o-DHmzwOOoB0hwbZ7014aCHbXBhY412WKcUjD1ik3bYgo34EMPGhzRYg6-0GwFbj1dRe6s9NlkcwQxZbbQ3kOmsBz-kx-hBr12CJ7f3Kfp2_vbr8v1i_endatmsF4axvF8vpOQFcN4ZCaAZp4ZQImktGC05M20JkJ-ia3lZcda1pNec9ZS1Vc8lhfIUvZ58D2O7h87k3lE7dYh2r-O1CtqqvyvebtUmXKn84VKQSmSHF7cOMXwfIQ1qb5MB57SHMCZFBSE1rStGMvr8H3QXxujzfopyKWVZiJpl6uVEmRhSitDfTVOQm7ZU3eSsjjln-Nmf89-hv4PNQDEBP6yD6_9YqQ_LdTOZ_gJLA7NP</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Mirzapoor Abbasabadi, Zohreh</creator><creator>Hamedi Asl, Dariush</creator><creator>Rahmani, Babak</creator><creator>Shahbadori, Rozhin</creator><creator>Karami, Sara</creator><creator>Peymani, Amir</creator><creator>Taghizadeh, Sara</creator><creator>Samiee Rad, Fatemeh</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202303</creationdate><title>KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients</title><author>Mirzapoor Abbasabadi, Zohreh ; Hamedi Asl, Dariush ; Rahmani, Babak ; Shahbadori, Rozhin ; Karami, Sara ; Peymani, Amir ; Taghizadeh, Sara ; Samiee Rad, Fatemeh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4498-f89971e77dc9eea472c020926842374cb3ee8428db73574db0fa74f24b5f792e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Biomarkers, Tumor - genetics</topic><topic>BRAF</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Class I Phosphatidylinositol 3-Kinases - genetics</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Drugs</topic><topic>Exons</topic><topic>Female</topic><topic>Genes</topic><topic>GTP Phosphohydrolases - genetics</topic><topic>Humans</topic><topic>Iran</topic><topic>K-Ras protein</topic><topic>Kinases</topic><topic>KRAS</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Membrane Proteins - genetics</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Mutation rates</topic><topic>NRAS</topic><topic>PIK3CA</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Proto-Oncogene Proteins p21(ras) - genetics</topic><topic>Risk factors</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mirzapoor Abbasabadi, Zohreh</creatorcontrib><creatorcontrib>Hamedi Asl, Dariush</creatorcontrib><creatorcontrib>Rahmani, Babak</creatorcontrib><creatorcontrib>Shahbadori, Rozhin</creatorcontrib><creatorcontrib>Karami, Sara</creatorcontrib><creatorcontrib>Peymani, Amir</creatorcontrib><creatorcontrib>Taghizadeh, Sara</creatorcontrib><creatorcontrib>Samiee Rad, Fatemeh</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mirzapoor Abbasabadi, Zohreh</au><au>Hamedi Asl, Dariush</au><au>Rahmani, Babak</au><au>Shahbadori, Rozhin</au><au>Karami, Sara</au><au>Peymani, Amir</au><au>Taghizadeh, Sara</au><au>Samiee Rad, Fatemeh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2023-03</date><risdate>2023</risdate><volume>37</volume><issue>5</issue><spage>e24868</spage><epage>n/a</epage><pages>e24868-n/a</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract>Aim
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC.
Method
To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer.
Results
KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations.
Conclusion
Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.
Mutations in KRAS, NRAS, BRAF, and PIK3CA genes are critical factors in clinical evaluation of colorectal cancer (CRC) development and progression. In Iran, however, the data regarding genetic profile of CRC patients is limited except for KRAS exon2 and BRAF V600F mutations. This study aimed to investigate the mutational spectrum and prognostic effects of these genes and explore the relationship between these mutations and clinicopathological features of CRC. To achieve these objectives, mutations in KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), PIK3CA (exons 9 and 20), and BRAF (exon 15) was determined using PCR and pyrosequencing in a total of 151 patients with colorectal cancer. KRAS, BRAF, NRAS, and PIK3CA mutations were identified in 41%, 5.96%, 3.97%, and 13.24% of the cases, respectively. There were some significant correlations between clinicopathological features and KRAS, PIK3CA, BRAF, and NRAS mutations. Mutations in KRAS and PIK3CA were shown to be independent risk factors for poor survival of the patients at stage I‐IV (p < 0.0001 and p = 0.001, respectively). No significant impact on prognosis was observed in patients with BRAF mutations. Our study revealed the prevalence of CRC biomarkers mutations in Iranian patients and emphasized the role of KRAS and PIK3CA on shorter overall survival rates in this population.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>36930789</pmid><doi>10.1002/jcla.24868</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8013 |
| ispartof | Journal of clinical laboratory analysis, 2023-03, Vol.37 (5), p.e24868-n/a |
| issn | 0887-8013 1098-2825 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10098058 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Aged Aged, 80 and over Antibodies Biomarkers, Tumor - genetics BRAF Cancer Cancer therapies Class I Phosphatidylinositol 3-Kinases - genetics Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Drugs Exons Female Genes GTP Phosphohydrolases - genetics Humans Iran K-Ras protein Kinases KRAS Lymphatic system Male Medical prognosis Membrane Proteins - genetics Metastasis Middle Aged Mutation Mutation rates NRAS PIK3CA Prognosis Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics Risk factors Survival Survival analysis Tumors Young Adult |
| title | KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T07%3A10%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KRAS,%20NRAS,%20BRAF,%20and%20PIK3CA%20mutation%20rates,%20clinicopathological%20association,%20and%20their%20prognostic%20value%20in%20Iranian%20colorectal%20cancer%20patients&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Mirzapoor%C2%A0Abbasabadi,%20Zohreh&rft.date=2023-03&rft.volume=37&rft.issue=5&rft.spage=e24868&rft.epage=n/a&rft.pages=e24868-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.24868&rft_dat=%3Cproquest_pubme%3E2800626540%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2799931864&rft_id=info:pmid/36930789&rfr_iscdi=true |